Greg Hamilton has over 25 years of management experience in molecular diagnostics, manufacturing, and professional services industries. Greg currently serves as CEO and Board member of io9, Inc. Prior to io9, he served as CEO and Executive Board member of Epigenomics AG, Board member of Eracal Therapeutics, CEO and Board member of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc., and Vice President of Operations at Hologic Inc.

Greg has been responsible for multiple FDA-cleared products, including the first-ever FDA-approved liquid biopsy test, a Human Papillomavirus (HPV) High-Risk Screening assay, and the first-ever cleared HPV genotyping assay.

Greg received his MBA from the University of Chicago and his B.S. in Finance from Purdue University.